The telehealth giant struck a partnership with Proximie, which uses augmented reality to let clinicians virtually “scrub in” to operating rooms.
The funding round boosted Flo’s valuation to $800 million. It plans to put the funds toward new technical capabilities and new hires.
Customers can order medicines for mild ailments, makeup, toiletries and more from 14 stores The pharmacy chain Boots will become the latest large retailer to make its products available through Deliveroo, as the takeaway delivery company aims to expand beyond restaurant orders. Stores in London, Birmingham, Edinburgh and Nottingham will be among the 14 initially …
Two months after Eli Lilly began an alliance with MiNA Therapeutics, a startup developing a new type of RNA therapy, the pharmaceutical giant is making a $15 million equity investment in its partner. MiNA is developing a new class of medicines called small activating RNA therapies.
As it makes a big push to expand in the U.S., digital health startup Babylon struck a deal to go public through a SPAC merger. The deal would value the company at $4.2 billion.
The Achilles Therapeutics IPO comes as several other biotechs make progress developing a type of cancer immunotherapy called a tumor-infiltrating lymphocyte. Clinical-stage Achilles contends its approach could best them all.
Fast growing UK telehealth provider Babylon Health bought a California-based practice as it looks to expand in the U.S. The company has several large contracts, including one to provide telehealth services to the U.K’s National Health Service.
DigitalHealth.London has announced the latest 20 small and medium sized businesses selected for its digital accelerator programme. The programme selects digital solutions or services with the highest potential to meet the city’s health and social care challenges. This the fifth year the event has been running and the NHS delivered programme will see funding matched …
The drug, AZD7442, is designed to potentially provide at least six months of protection from Covid-19. The trial, which is funded by federal defense and health authorities in the U.S., is enrolling up to 48 healthy volunteers in the U.K. AstraZeneca’s double-antibody approach is similar to that of Regeneron and Roche with their drug, REGN-COV2.
The company said Tuesday that a final analysis of its Phase IIb/III study of cabotegravir showed greater efficacy in HIV prevention than Gilead’s Truvada. The study, among men and transgender women who have sex with men, was stopped in May following an interim analysis.